Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines, with Novartis Pharma’s radioligand therapy Pluvicto (lutetium vipivotide tetraxetan (177Lu)) forecast to achieve the highest peak sales among them. The…
To read the full story
Related Article
- Alfresa Launches Neffy Nasal Spray for Anaphylaxis in Japan
February 13, 2026
- Pfizer Releases Nurtec Migraine Drug in Japan
December 17, 2025
- Izervay, Vorzzz, Dormicum Syrup Now Available in Japan
November 28, 2025
- Otsuka’s Hypercholesterolemia Med Nexletol Hits Japan Shelves
November 25, 2025
- Pluvicto, Imaavy, Hernexeos Now Available in Japan
November 13, 2025
- Servier’s Voranigo Skips November Listing; GSK, BMS Drugs Also Absent
November 6, 2025
- Japan Approves Pluvicto, Izervay, and Lots More; Subcutaneous Rybrevant Not on Roster
September 22, 2025
REGULATORY
- Japan to Consider Support for Domestic Immunoglobulin Production: Minister
July 16, 2026
- Govt Set to Amend Honebuto Draft over Inflation, MFN Language
July 16, 2026
- HHS Report Puts Japan’s Drug Innovation Financing Well Behind US
July 15, 2026
- MHLW Orders Label Revisions for PPIs, Checkpoint Inhibitors
July 15, 2026
- Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…